伽玛刀联合吉西他滨治疗局部晚期胰腺癌的Ⅰ期临床观察  

A phase Ⅰ study of gemcitabine combined with gamma knife therapy for locally advanced pancreatic cancer

作　　者：俞立权[1] 曹京旭[1] 程海民[2] 杨远游[2] 史铭[1] 宋薇[1] 王迎选[1] 

机构地区：[1]武警总医院肿瘤一科,北京100039 [2]武警总医院伽玛刀治疗中心,北京100039

出　　处：《武警医学》2013年第10期881-883,共3页Medical Journal of the Chinese People's Armed Police Force

摘　　要：目的探索吉西他滨联合伽玛刀治疗局部晚期胰腺癌的最适剂量。方法采用"3+3"试验设计模式,患者接受伽玛刀和吉西他滨治疗,伽玛刀治疗计划52 Gy/13F,吉西他滨初始剂量700 mg/m2,每周1次,连续3周,剂量按照100 mg/m2依次递增,直至出现剂量限制性毒性反应。结果入组9例患者,700 mg/m2和800 mg/m2组完成治疗计划,当吉西他滨的剂量递增至900 mg/m2时出现剂量限制性的血液学毒性反应,试验中止。结论伽玛刀联合吉西他滨治疗局部晚期胰腺癌,吉西他滨的推荐剂量为800 mg/m2,每周1次,连续3周。Objective To estimate the optimal dose of gemcitabine administered concurrently with gamma knife therapy in patients with locally advanced pancreatic cancer. Method “3＋3” model was measured in the study. Eligible patients had histologically confirmed pancreatic adenocarcinoma deemed locally unresectable. Patients received gamma knife therapy （52 Gy/13F） with concurrent infused weekly gemcitabine（dose escalated from 700 mg/m2 to 900 mg/m2 weekly） until dose-restricted toxicity. Results 9 patients were enrolled. Patients enrolled in gemcitabine 700 mg/m2 and 800 mg/m2 completed the plan.Ⅲ-Ⅳ degree hematology toxicity was seen in patients when gemcitabine dose escalated to 900 mg/m2. Conclutions The combination of gemcitabine and gamma knife therapy is well tolerated. The optimal dose of gemcitabine is 800 mg/m2 weekly.

关 键 词：伽玛刀 吉西他滨 胰腺癌 

分 类 号：R735.9[医药卫生—肿瘤]